Chronic Kidney Disease Stage 1NCT05225454
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
An observational study of Chronic Kidney Disease Stage 1 and Chronic Kidney Disease Stage 2, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
Trial summary
Used multi-year health examination member profile by multi-algorithms technology, to find comprehensive key hazard factors or important high-risk group components for metabolic syndrome and chronic kidney disease or more common chronic diseases. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
- How many people
- 81,108 participants
- Where
- 1 siteTaiwan
- Study dates
- 3 Mar 2021to 31 Jul 2024
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: In 2006-2017 of the MJ Health Research Foundation's member, of the de-linked and de-identified annual health check database, about 71,108 people; 2015-2020, the Health2Sync provides [Intelligent Anti-Glucose System], the biometric and behavioral item de-linked and de-identified data, about 10,000 people.
Who may be able to join
- Continuously health screening twice or more in MJ health reports.
- Chronic kidney disease
- Metabolic syndrome
- Or more, common chronic diseases
Who cannot join
- Participants who have received clinical treatment
- Subjects of other related research diseases
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Oriental Institute of Technology / Far Eastern Memorial Hospital
New Taipei City, Pan-Chiao Dist., 22061
About this study
Used multi-year health examination member profile by multi-algorithms technology, to find comprehensive key hazard factors or important high-risk group components for metabolic syndrome and chronic kidney disease or more common chronic diseases.
Read the detailed description
The proportion of the population over the age of 65 in Taiwan reached 7.10% in 1993. After Taiwan became an 「aging country」, the originally slow growth of the elderly population (9.9% in 2006) started to increase, and it reached 14.05% in 2018, which was almost 2 times that in 1993. In addition, Taiwan formally became an 「aged country」as defined globally. According to the statistical data from the Ministry of the Interior and the data from the National Development Council, it is estimated that the population over the age of 65 is rapidly growing. It is expected that 6 years later (by 2026), the elderly population in Taiwan will exceed 20%. Taiwan will formally become the「super-aged country」as defined globally, with a population structure similar to that in Japan, South Korea, Singapore, and some European countries (Department of Statistics, 2018; National Development Council, 2019). In order to effectively prevent and treat chronic diseases of sub-health populations and develop health management prediction systems that have unlimited market opportunities and potentials, the author intends to extend the achievements of individual projects sponsored by the Ministry of Science and Technology in recent years. By multi-year complete health examination member profile, this project used multiple algorithms, such as Logistic regression (LR); Classification And Regression Trees (CART); Hierarchical Linear Modeling (HLM); Random forests (RF); Support-Vector Machines (SVM); eXtreme Gradient Boosting (xGBoost); Light Gradient Boosting Machine (LightGBM) and multiple analysis tools to explore the common potential health hazard variables of the sub-health population to establish a comprehensive assessment health management system that can detect chronic diseases early, the research results will be provided for reference in related fields.
- Conditions
- Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Metabolic Syndrome
- Medical subject headings
- Renal Insufficiency, Chronic, Metabolic Syndrome, Chronic Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Other
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with metabolic syndrome in kidney disease-related adverse events as assessed by estimated glomerular filtration rate
Physiological information of participants with chronic kidney disease related adverse events as assessed in metabolic syndrome, by natural longitudinal change from baseline in estimated glomerular filtration rate at 2 years recent in health screening in participants.
Measured: 2 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2022
- Study start3 Mar 2021
- Primary completion3 Jul 2024 (estimated)
- Study completion31 Jul 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney Disease Stage 1Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 81,108 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Far Eastern Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05225454
- Sponsor's protocol ID
- 110027-E
- Status last verified
- Mar 2022
- First submitted
- 21 Oct 2021
- Last updated
- 10 May 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
- ClinicalTrials.gov ID
- NCT05225454
- Acronym / sponsor ID
- 110027-E
- Conditions
- Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Metabolic Syndrome
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 81,108 participants (estimated)
- Lead sponsor
- Far Eastern Memorial HospitalUniversity, hospital or other
- Study start
- 3 Mar 2021 (actual)
- Primary completion
- 3 Jul 2024 (estimated)
- Study completion
- 31 Jul 2024 (estimated)
- First posted
- 4 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Used multi-year health examination member profile by multi-algorithms technology, to find comprehensive key hazard factors or important high-risk group components for metabolic syndrome and chronic kidney disease or more common chronic diseases.
Detailed description
The proportion of the population over the age of 65 in Taiwan reached 7.10% in 1993. After Taiwan became an 「aging country」, the originally slow growth of the elderly population (9.9% in 2006) started to increase, and it reached 14.05% in 2018, which was almost 2 times that in 1993. In addition, Taiwan formally became an 「aged country」as defined globally. According to the statistical data from the Ministry of the Interior and the data from the National Development Council, it is estimated that the population over the age of 65 is rapidly growing. It is expected that 6 years later (by 2026), the elderly population in Taiwan will exceed 20%. Taiwan will formally become the「super-aged country」as defined globally, with a population structure similar to that in Japan, South Korea, Singapore, and some European countries (Department of Statistics, 2018; National Development Council, 2019). In order to effectively prevent and treat chronic diseases of sub-health populations and develop health management prediction systems that have unlimited market opportunities and potentials, the author intends to extend the achievements of individual projects sponsored by the Ministry of Science and Technology in recent years. By multi-year complete health examination member profile, this project used multiple algorithms, such as Logistic regression (LR); Classification And Regression Trees (CART); Hierarchical Linear Modeling (HLM); Random forests (RF); Support-Vector Machines (SVM); eXtreme Gradient Boosting (xGBoost); Light Gradient Boosting Machine (LightGBM) and multiple analysis tools to explore the common potential health hazard variables of the sub-health population to establish a comprehensive assessment health management system that can detect chronic diseases early, the research results will be provided for reference in related fields.
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 10 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- In 2006-2017 of the MJ Health Research Foundation's member, of the de-linked and de-identified annual health check database, about 71,108 people; 2015-2020, the Health2Sync provides [Intelligent Anti-Glucose System], the biometric and behavioral item de-linked and de-identified data, about 10,000 people.
Key inclusion criteria (4 listed)
- Continuously health screening twice or more in MJ health reports.
- Chronic kidney disease
- Metabolic syndrome
- Or more, common chronic diseases
Key exclusion criteria (2 listed)
- Participants who have received clinical treatment
- Subjects of other related research diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Other | – |
Primary outcome
Number of participants with metabolic syndrome in kidney disease-related adverse events as assessed by estimated glomerular filtration rate
Time frame: 2 year
Physiological information of participants with chronic kidney disease related adverse events as assessed in metabolic syndrome, by natural longitudinal change from baseline in estimated glomerular filtration rate at 2 years recent in health screening in participants.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2022.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Disease Stage 1
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingPhase 1
Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
End Stage Renal Disease
Not yet recruitingPhase 2
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Type 1 Diabetes Mellitus With Diabetic Nephropathy
Not yet recruitingPhase 1
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Systemic Lupus Erythematosus, Sjögren's Disease
RecruitingPhase 1/2
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
Healthy Volunteers, Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Disease Stage 1 and Chronic Kidney Disease Stage 2, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with metabolic syndrome in kidney disease-related adverse events as assessed by estimated glomerular filtration rate (time frame: 2 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2022.